Keywords
Tumor biomarker
Thyroglobulin
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To review the literature on tumor markers and the risk of recurrence of differentiated thyroid cancer in adult patients. Literature review: Serum thyroglobulin (Tg) measurement is a test with several limitations, which can determine falsely low results. Despite this, it is an easily accessible test and its use in clinical practice contributes to early screening for recurrence or persistence of DTC when there is still no presence of structural disease detectable on imaging methods. After initial surgical treatment, all patients must be staged and stratified according to the risk of recurrence for DTC with assessments including tumor markers and, when necessary, imaging tests to screen for residual disease. Final considerations: Thyroglobulin and antithyroglobulin are tumor markers with a fundamental role in monitoring patients after surgical treatment of thyroid cancer. However, other strategies can be used to improve screening for structural DTC disease, using imaging tests such as computed tomography, MRI, full body research with Iodine 313 and Pet Scan.
References
BASTOS NETO BC, et al. Incidência do câncer de tireoide na população brasileira, 2006 a 2015. Revista da AMRIGS. 2019; 63(3): 307-312.
BÍLEK R, et al. Iodine, thyroglobulin and thyroid gland. Psysiol Res. 2020; 69(2): 225-236.
COSCIA F, et al. The structure of human thyroglobulin. Nature. 2020; 578(7796): 627-630.
DALTROZO JB, et al. Perfil dos pacientes com câncer diferenciado de tireoide em acompanhamento no ambulatório de endocrinologia do Hospital Universitário de Florianópolis. Arquivos Catarinenses de Medicina. 2010; 39(2); 68-71.
FOURNIER DM, et al. Second Primary Malignancies in Cancer Survivors. The Journal for Nurse Practitioners. 2018; 14(4): 238-244.
GEUS-OEI L, et al. Sensitivity of 123I whole-body scan and thyroglobulin in the detection of metastases or recurrent differentiated thyroid câncer. Eur J Nucl Med Mol Imaging. 2002; 29(6): 768-74.
GOLBERT L, et al. Carcinoma diferenciado de tireoide: avaliação inicial e acompanhamento. Arq Bras Endocrinolo Metab. 2005; 49(5): 701-710.
GONÇALVES LF, et al. Efetividade da alimentação na prevenção do câncer de tireoide: Revisão Sistemática. Revista Brasileira de Cancerologia. 2020; 66(4): 1-8.
HAUGEN BR, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016; 26(1): 1-133.
KINSCHOT CMJ, et al. Thyroglobulin and thyroglobulin antibodies: assay-dependent management consequences in patients with differentiated thyroid carcinoma. Clin Chem Lab Med. 2022; 60(5): 756-765.
LI S, et al. The Role of Thyroglobulin in Preoperative and Postoperative Evaluation of Patients With Differentiated Thyroid Cancer. Front Endocrinol. 2022; 13:1-12.
MILHOMEM E, et al. Perfil epidemiológico de pacientes com diagnóstico de carcinoma diferenciado de tireoide em seguimento em ambulatório de endocrinologia. Rev Soc Bras Clin Med. 2019; 17(2): 90-2.
PRPIC M, et al. Thyroglobulin as a tumor marker in differentiated thyroid câncer- clinical considerations. Acta Clin Croat. 2018; 57(3): 518-527.
QIN J, et al. High Thyroglobulin Antibody Levels Increase the Risk of Differentiated Thyroid Carcinoma. Dis Markers. 2015; 2015: 1-7.
ROCHA SC, et al. O papel da tireoglobulina sérica no câncer diferenciado de tireoide. Brazilian Journal of Surgery and Clinical Research. 2021; 36(1): 72-77.
ROSÁRIO PW, et al. Nódulo tireoidiano e câncer diferenciado de tireoide: atualização do consenso brasileiro. Arq Bras Endocrinol Metab. 2013; 3(57): 1-25.
SPENCER C, et al. Thyroglobulin antibody (TgAb) methods - Strengths, pitfalls and clinical utility for monitoring TgAb-positive patients with differentiated thyroid câncer. Best Pract Res Clin Endocrinol Metab. 2013; 27(5): 701-712.
TESSLER FN, et al. ACR Thyroid Imaging, Reporting and Data System (TI-RADS): White Paper of the ACR TI-RADS Committee. J Am Coll Radiol. 2017; 14(5): 587-595.
VARANDAS VM, et al. Repercussão clínica da reclassificação dos carcinomas diferenciados de tireoide de acordo com a 6ª edição do TNM. Arq Bras Endocrinol Metab. 2007; 51(5): 1-7.
VIANNA DM, et al. The histological rarity of thyroid câncer. Braz J Otorhinolaryngol. 2012; 78(2): 48-51.
XÚ Y, et al. Diagnostic value of cytology, thyroglobulin, and combination of them in fine-needle aspiration of metastatic lymph nodes in patients with differentiated thyroid cancer. Medicine. 2019; 98(45): 1-9.